drugset / Trial / NCT01450124

Safety, Tolerability And Mechanism Of Action Of Boswellic Acids (BA) In Multiple Sclerosis (SABA)

NCT01450124 ↗

Phase 2 Completed 29 enrolled University Medical Center Hamburg-Eppendorf
NaSingle-groupOpen-labelTreatment

Summary

To determine the safety and tolerability of BOSWELAN in subjects with multiple sclerosis or clinically isolated syndrome and to describe the effect of Boswellic acids on the disease activity as assessed by monthly MRI measures.

Timeline

Start
2011-09
Primary completion
2014-12
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Boswellic acids Unknown 400 mg Oral
Subject Boswellic acids Unknown 1600 mg Oral